argenx SE (ARGNF) Stock Price & Analysis
argenx SE (ARGNF) — price $936.00 (0.00%), as of the Oct 2, 2026 trading session; market cap $58.2B. Expected results Oct 22, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.23× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 22, 2026
argenx SE · ARGNF · Healthcare · Biotechnology
argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $936.00 | |
| Change on the day | 0.00% | |
| 52-week range | $708.72 – $1020.00 | |
| Market capitalisation | $58.2B | |
| Price / earnings (trailing) | 33.00 | |
| Shares traded on the day | 49 | |
| Beta (volatility vs the S&P 500) | -0.02 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We believe a first-in-class launch in myositis can establish the foundation for broader leadership in rheumatology with data expected in the second half of 2027.
Karen Massey · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for argenx SE (ARGNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ARGNF film — every key number, told as a short cinematic story
~2 min · open the film
What is argenx SE (ARGNF), and what does it report?
Short answer · as of
argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. argenx SE (ARGNF) is classified as Healthcare / Biotechnology. SEC filing business address: Industriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde. It employs 1,863 people and is led by Karen Massey. In Q2 FY2026 it reported revenue of $2.75B and net income of $820M. The market values it at $58.2B.
What do the latest results show for argenx SE (ARGNF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2.75B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $2.75B Jun 30, 2026
- Latest quarter · R&D
- $909.54M Jun 30, 2026
- Latest quarter · SG&A
- $755.83M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $828.28M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $2.75B | $909.54M | $755.83M | $828.28M |
| Dec 31, 2025 | $2.43B | $724.77M | $336.29M | $664.96M |
| Jun 30, 2025 | $947.96M | $327.70M | $321.35M | $201.06M |
| Dec 31, 2024 | $790.68M | $297.23M | $563.64M | $16.17M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.43B May 7, 2026
- Latest report · revenue estimate
- $1.45B May 7, 2026
- Latest report · revenue vs estimate
- Above estimate May 7, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| May 7, 2026 | $2.43B | $1.45B | $14.3800 | Not available |
| Oct 30, 2025 | $947.96M | $1.28B | $7.3300 | Not available |
| May 8, 2025 | $790.68M | $861.83M | $2.7800 | Not available |
| Oct 31, 2024 | $841.96M | $665.08M | −$0.5100 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.75B | $820M | $12.74 (diluted) |
| Q4 FY2025 | $2.43B | $883M | $13.34 (diluted) |
| Q2 FY2025 | $948M | $245M | $6.32 (diluted) |
| Q4 FY2024 | $791M | $169M | $2.58 (diluted) |
What are the financial strengths and risks for argenx SE (ARGNF)?
Short answer
Cash and short-term investments were $5.18B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $735.27M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway. The distress and quality screens read Altman Z 21.41 · Piotroski F 5. Trailing ratios: ROE 16.8% · ROA 13.0% · current ratio 5.23 · earnings yield 2.2% · free-cash-flow yield 1.4%.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $735.27M Jun 30, 2026
- Previous quarter · operating cash flow
- $386.75M Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $735.27M | −$2.94M |
| Dec 31, 2025 | $386.75M | −$610,000 |
| Jun 30, 2025 | $468.50M | −$5.62M |
| Dec 31, 2024 | $40.45M | −$960,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at argenx SE (ARGNF)?
Short answer · as of
The next earnings report is expected on Oct 22, 2026.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We believe a first-in-class launch in myositis can establish the foundation for broader leadership in rheumatology with data expected in the second half of 2027.
Karen Massey ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about argenx SE (ARGNF)?
ARGNF Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the ARGNF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ARGNF a good stock to buy?
Stock Expert AI does not rate ARGNF buy, sell or hold. argenx SE has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ARGNF stock price today?
The last price recorded on this page for argenx SE (ARGNF) is $936.00, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ARGNF?
The main risks for argenx SE include clinical trial failures for its product candidates, particularly efgartigimod, which is in late-stage development.
What are the key factors to evaluate for ARGNF?
Evaluate ARGNF on fundamentals, analyst consensus, and risk factors. P/E: 33.00x. Lead product candidate, efgartigimod, in Phase III clinical trials for multiple autoimmune indications, representing near-term revenue potential. Not financial advice.
How frequently does ARGNF data refresh on this page?
ARGNF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ARGNF's recent stock price performance?
argenx SE (ARGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for antibody development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARGNF overvalued or undervalued right now?
argenx SE (ARGNF) trades at 33.00x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ARGNF before investing?
Before investing in argenx SE (ARGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (67 figures)
The 67 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Karen Massey (Jul 23, 2026): We believe a first-in-class launch in myositis can establish the foundation for broader leadership in rheumatology with data expected in the second half of 2027. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Industriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Laarderhoogtweg 25, Amsterdam, NH, 1101 EB, NL". The FMP company description names Breda as the headquarters; this page uses the address in this row. |
FMP — 59 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 22, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $936.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T10:45:03.292Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $58.2B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T10:45:02.273Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 33.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 49 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -0.02 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | |
id.employees | Employees | 1,863 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Karen Massey | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $2.75B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $820M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
id.founder | Founder named in the filing | Timothy Van Hauwermeiren EMBA — Co-Founder & Non-Independent Non-Executive Chairman of the Board | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $528.27M, net result −$408.26M; FY2022 revenue $441.01M, net result −$709.59M; FY2023 revenue $1.23B, net result −$295.05M; FY2024 revenue $2.25B, net result $833.04M; FY2025 revenue $4.32B, net result $1.34B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 89.9% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $2.75B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $909.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $755.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $828.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $2.43B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $724.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $336.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $664.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.revenue_k | Revenue — period end 2025-06-30 | $947.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.rd_k | R&D — period end 2025-06-30 | $327.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.sga_k | SG&A — period end 2025-06-30 | $321.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.operating_result_k | FMP standardized operating result — period end 2025-06-30 | $201.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.revenue_k | Revenue — period end 2024-12-31 | $790.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.rd_k | R&D — period end 2024-12-31 | $297.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.sga_k | SG&A — period end 2024-12-31 | $563.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.operating_result_k | FMP standardized operating result — period end 2024-12-31 | $16.17M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $2.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $1.45B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $14.3800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_actual | Revenue · reported — report date 2025-10-30 | $947.96M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_estimated | Revenue · estimate — report date 2025-10-30 | $1.28B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_actual | EPS · reported — report date 2025-10-30 | $7.3300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.revenue_actual | Revenue · reported — report date 2025-05-08 | $790.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.revenue_estimated | Revenue · estimate — report date 2025-05-08 | $861.83M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.eps_actual | EPS · reported — report date 2025-05-08 | $2.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-31.revenue_actual | Revenue · reported — report date 2024-10-31 | $841.96M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-31.revenue_estimated | Revenue · estimate — report date 2024-10-31 | $665.08M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-31.eps_actual | EPS · reported — report date 2024-10-31 | −$0.5100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $5.18B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $735.27M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $68.93M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $47.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 6.72× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $735.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $386.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$2.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$610,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.operating_cash_flow_m | Operating cash flow — period end 2025-06-30 | $468.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.capex_m | Capital expenditure (reported) — period end 2025-06-30 | −$5.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.operating_cash_flow_m | Operating cash flow — period end 2024-12-31 | $40.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.capex_m | Capital expenditure (reported) — period end 2024-12-31 | −$960,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $708.72 – $1020.00 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 21.41 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 16.8% · ROA 13.0% · current ratio 5.23 · earnings yield 2.2% · free-cash-flow yield 1.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 11.23× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $5.18B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-05-07.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($2.43B) with the recorded estimate ($1.45B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-06-30.revenue_k,fin.q_table.depth.2025-06-30.rd_k,fin.q_table.depth.2025-06-30.sga_k,fin.q_table.depth.2025-06-30.operating_result_k,fin.q_table.depth.2024-12-31.revenue_k,fin.q_table.depth.2024-12-31.rd_k,fin.q_table.depth.2024-12-31.sga_k,fin.q_table.depth.2024-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-05-07. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.revenue_actual.comparison,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2025-10-30.revenue_actual,earn.history.depth.2025-10-30.revenue_estimated,earn.history.depth.2025-10-30.eps_actual,earn.history.depth.2025-05-08.revenue_actual,earn.history.depth.2025-05-08.revenue_estimated,earn.history.depth.2025-05-08.eps_actual,earn.history.depth.2024-10-31.revenue_actual,earn.history.depth.2024-10-31.revenue_estimated,earn.history.depth.2024-10-31.eps_actual. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-06-30.operating_cash_flow_m,fin.opcf.depth.2025-06-30.capex_m,fin.opcf.depth.2024-12-31.operating_cash_flow_m,fin.opcf.depth.2024-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.